Virtual trials and the next generation of pharma clinical researchPreviously viewed as a ‘nice to have’ for the pharma industry, virtual trials were already moving from a Share XVirtual trials and the next generation of pharma clinical researchhttps://pharmaphorum.com/webinars/nihr-virtual-trials-pharma-research/
Assessing the impact of prevalence on pricing of rare disease drugs in GermanyIn this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss Share XAssessing the impact of prevalence on pricing of rare disease drugs in Germanyhttps://pharmaphorum.com/views-analysis-market-access/assessing-pricing-of-rare-disease-drugs-in-germany/
2021 market access prospects for ItalyItaly was working up big changes in market access throughout 2020 which will be implemented in 2021. In Share X2021 market access prospects for Italyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-italy/
AstraZeneca on diversity: the pharmaphorum podcastThe theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by Share XAstraZeneca on diversity: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/astrazeneca-rebekah-martin-diversity/
Gene editing: beyond the hypeGenome editing is an exciting but still nascent field, and companies in the area face as many obstacles Share XGene editing: beyond the hypehttps://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/
COVID drives a customer experience shift in life sciences CRMThe future of life sciences CRM will be defined by rapid digital transformation and a focus on customer Share XCOVID drives a customer experience shift in life sciences CRMhttps://pharmaphorum.com/views-analysis-sales-marketing/covid-drives-a-customer-experience-shift-in-life-sciences-crm/
Patients as Partners Europe: Are we doing patient centricity all wrong?To be truly patient centric, do we need to turn the current model on its head and work Share XPatients as Partners Europe: Are we doing patient centricity all wrong?https://pharmaphorum.com/views-analysis-patients/pharma-patients-as-partners-europe-patient-centricity/
The US biosimilar market: Predictions for 2021It has been five years since the first biosimilar launched in the United States market—marking the first steps Share XThe US biosimilar market: Predictions for 2021https://pharmaphorum.com/views-and-analysis/biosimilar-market-predictions-2021/
Unlocking health data to improve oncology outcomesAs the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial Share XUnlocking health data to improve oncology outcomeshttps://pharmaphorum.com/r-d/views-analysis-r-d/unlocking-health-data-to-improve-oncology-outcomes-2/
